{ "company": "Natera", "ticker": "NTRA", "period": { "from": "2026-03-13", "to": "2026-04-12", "days": 30 }, "sentiment_breakdown": { "positive": 38, "negative": 37, "neutral": 31 }, "synthesis": { "executive_summary": "Sentiment analysis for Natera (NTRA) from 2026-03-13 to 2026-04-12. Analyzed 106 items across FDA and news sources.", "key_findings": [], "overall_sentiment": "neutral" }, "top_positive": [ { "title": "20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform", "date": "2026-04-08", "source": "alpha_vantage", "score": 0.812 }, { "title": "20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform", "date": "2026-04-07", "source": "alpha_vantage", "score": 0.812 }, { "title": "Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study.", "date": "2026 Mar 2", "source": "pubmed", "score": 0.753 }, { "title": "Dakota Wealth Management Buys Shares of 5,921 Natera, Inc. $NTRA", "date": "2026-03-29", "source": "alpha_vantage", "score": 0.66 }, { "title": "Oncology Precision Medicine Market Trends and Investment Opportunities 2026-2030 - Advancements in CAR-T and Gene Therapies Propel Precision Oncology Growth", "date": "2026-03-27", "source": "news", "score": 0.637 }, { "title": "Court Win on MRD Patents and Royalties Might Change The Case For Investing In Natera (NTRA)", "date": "2026-04-10", "source": "alpha_vantage", "score": 0.586 }, { "title": "Natera wins 30% ongoing royalty in patent case against Invitae By Investing.com", "date": "2026-04-09", "source": "alpha_vantage", "score": 0.572 }, { "title": "56,665 Shares in Natera, Inc. $NTRA Purchased by Robinhood Asset Management LLC", "date": "2026-04-07", "source": "alpha_vantage", "score": 0.572 }, { "title": "Natera, Inc. $NTRA Shares Sold by Assenagon Asset Management S.A.", "date": "2026-03-28", "source": "alpha_vantage", "score": 0.572 }, { "title": "Wealth Enhancement Advisory Services LLC Has $11.48 Million Stock Position in Natera, Inc. $NTRA", "date": "2026-03-27", "source": "alpha_vantage", "score": 0.494 } ], "top_negative": [ { "title": "Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER(+) HER2(-) locally-advanced or metastatic breast cancer.", "date": "2026 Apr 1", "source": "pubmed", "score": -1.0 }, { "title": "Colorectal Cancer Advocates Urge Congress to Fund New Research", "date": "2026-03-27", "source": "news", "score": -0.945 }, { "title": "Testing for hereditary cancer genes in men: a missed opportunity for cancer prevention.", "date": "2026-04-12", "source": "pubmed", "score": -0.848 }, { "title": "The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II study.", "date": "2026 Mar 1", "source": "pubmed", "score": -0.832 }, { "title": "Utility of Circulating Tumor DNA-Based Liquid Biopsies in Patients with Cancer Receiving Immunotherapy.", "date": "2026-04-12", "source": "pubmed", "score": -0.791 }, { "title": "Blood test helped some women over 70 with breast cancer avoid surgery", "date": "2026-03-31", "source": "alpha_vantage", "score": -0.765 }, { "title": "Colorectal Cancer and Mortality Risk Among Older Adults With vs Without Adenoma on Prior Colonoscopy.", "date": "2026 Apr 9", "source": "pubmed", "score": -0.758 }, { "title": "Signatera Data in Older Breast Cancer Patients Could Be A Game Changer For Natera (NTRA)", "date": "2026-04-01", "source": "alpha_vantage", "score": -0.66 }, { "title": "Natera's Signatera Data Suggests Select Breast Cancer Patients Could Skip Surgery", "date": "2026-03-31", "source": "alpha_vantage", "score": -0.66 }, { "title": "New prognostic and predictive scoring systems for colorectal cancer liver metastases.", "date": "2026 Apr 9", "source": "pubmed", "score": -0.66 } ], "raw_data": { "total_items": 106, "items": [ { "source": "news", "source_name": "GlobeNewswire", "title": "Rapid Growth in Cell-Free Tumor DNA Detection Market: Forecast to Reach $5.64 Billion by 2030 as Advancements in Personalized Medicine Propel Expansion", "description": "Dublin, April 07, 2026 (GLOBE NEWSWIRE) -- The \"Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market Report 2026\" has been added to ResearchAndMarkets.com's offering.", "url": "https://www.globenewswire.com/news-release/2026/04/07/3269503/28124/en/Rapid-Growth-in-Cell-Free-Tumor-DNA-Detection-Market-Forecast-to-Reach-5-64-Billion-by-2030-as-Advancements-in-Personalized-Medicine-Propel-Expansion.html", "date": "2026-04-07", "published_at": "2026-04-07T16:23:00Z", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Colorectal Cancer Advocates Urge Congress to Fund New Research", "description": "With Young Lives at Stake, More Than 250 Colorectal Cancer Advocates Demand Action With Young Lives at Stake, More Than 250 Colorectal Cancer Advocates Demand Action", "url": "https://www.globenewswire.com/news-release/2026/03/27/3263970/0/en/Colorectal-Cancer-Advocates-Urge-Congress-to-Fund-New-Research.html", "date": "2026-03-27", "published_at": "2026-03-27T16:31:00Z", "sentiment": { "label": "negative", "score": -0.945, "confidence": 0.95 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Oncology Precision Medicine Market Trends and Investment Opportunities 2026-2030 - Advancements in CAR-T and Gene Therapies Propel Precision Oncology Growth", "description": "Dublin, March 27, 2026 (GLOBE NEWSWIRE) -- The \"Oncology Precision Medicine Market Report 2026\" has been added to ResearchAndMarkets.com's offering. ...", "url": "https://www.globenewswire.com/news-release/2026/03/27/3263857/28124/en/Oncology-Precision-Medicine-Market-Trends-and-Investment-Opportunities-2026-2030-Advancements-in-CAR-T-and-Gene-Therapies-Propel-Precision-Oncology-Growth.html", "date": "2026-03-27", "published_at": "2026-03-27T14:44:00Z", "sentiment": { "label": "positive", "score": 0.637, "confidence": 0.64 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results", "description": "NASHVILLE, Tenn., March 26, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its fourth quarter results:", "url": "https://www.globenewswire.com/news-release/2026/03/26/3263407/0/en/IMDX-Submits-GraftAssureDx-for-FDA-Review-and-Reports-Q4-2025-Results.html", "date": "2026-03-26", "published_at": "2026-03-26T20:05:00Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Predictive Biomarkers Market to Reach USD 156.85 Billion by 2035; Rising Adoption of Precision Medicine and Targeted Therapies Driving Market Growth – SNS Insider", "description": "Rising Chronic Disease Burden, AI-Driven Biomarker Discovery, and Expanding Companion Diagnostics Pipelines Fuel Unprecedented Market Expansion. Rising Chronic Disease Burden, AI-Driven Biomarker Discovery, and Expanding Companion Diagnostics Pipelines Fuel U…", "url": "https://www.globenewswire.com/news-release/2026/03/17/3257053/0/en/Predictive-Biomarkers-Market-to-Reach-USD-156-85-Billion-by-2035-Rising-Adoption-of-Precision-Medicine-and-Targeted-Therapies-Driving-Market-Growth-SNS-Insider.html", "date": "2026-03-17", "published_at": "2026-03-17T11:45:00Z", "sentiment": { "label": "negative", "score": -0.477, "confidence": 0.48 } }, { "source": "sec", "filing_type": "8-K", "title": "8-K - Current report", "date": "2026-04-01", "url": "https://www.sec.gov/Archives/edgar/data/1604821/000110465926038519/0001104659-26-038519-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera Claims Top Trading Volume as Legal Victory Sparks $550 Million Surge Amid Price Drop", "url": "https://www.bitget.com/amp/news/detail/12560605357844", "date": "2026-04-11", "summary": "Natera Inc. (NTRA) experienced a significant $550 million surge in trading volume despite a 4.91% price drop, following a favorable legal ruling that increased royalty rates from 10% to 30% on infringing MRD-related product sales. This legal victory strengthens Natera's intellectual property in the oncology diagnostics market but was met with profit-taking or reassessment by investors. The market is now keenly watching how these legal developments will translate into financial results in upcomin", "sentiment_score": 0.105288, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.052, "confidence": 0.05 } }, { "source": "alpha_vantage", "title": "Natera awarded 30% ongoing royalty in MRD patent litigation", "url": "https://www.msn.com/en-us/money/companies/natera-awarded-30-ongoing-royalty-in-mrd-patent-litigation/ar-AA20uqCc?uxmode=ruby&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "date": "2026-04-10", "summary": "Natera has been awarded a 30% ongoing royalty in its patent litigation concerning minimal residual disease (MRD) testing. This outcome follows an earlier court ruling that found certain of Natera's intellectual property was infringed. The royalty likely applies to future sales or activities related to the infringed patents.", "sentiment_score": 0.80116, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.226, "confidence": 0.23 } }, { "source": "alpha_vantage", "title": "Court Win on MRD Patents and Royalties Might Change The Case For Investing In Natera (NTRA)", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/court-win-on-mrd-patents-and-royalties-might-change-the-case", "date": "2026-04-10", "summary": "Natera recently secured a favorable court ruling, upholding the validity of its three MRD patents and granting a 30% royalty on infringing product sales. This decision bolsters Natera's intellectual property in molecular residual disease testing, potentially enhancing its market position and revenue outlook. While strengthening Natera's investment narrative, the article notes that investors should still consider risks such as high cash burn and challenges in clinical trials and reimbursement.", "sentiment_score": 0.427997, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.586, "confidence": 0.59 } }, { "source": "alpha_vantage", "title": "Director Eric H. Rubin joins Natera (NTRA) insider roster with Form 3 filing", "url": "https://www.stocktitan.net/sec-filings/NTRA/form-3-natera-inc-initial-statement-of-beneficial-ownership-d9ef1efdbc22.html", "date": "2026-04-10", "summary": "Natera, Inc. (NTRA) director Eric H. Rubin has filed an initial Form 3 with the SEC, formally establishing his status as an insider. This filing indicates that Rubin is a director of the company and brings him under insider reporting requirements, though it does not report any beneficial ownership of securities or trading activity. The Form 3 serves as an initial statement of beneficial ownership, providing transparency on his new insider role.", "sentiment_score": 0.047032, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Judge Hands Natera 30% Ongoing Royalty In MRD Patent Battle", "url": "https://www.benzinga.com/markets/equities/26/04/51727487/judge-hands-natera-30-ongoing-royalty-in-mrd-patent-battle", "date": "2026-04-09", "summary": "A Delaware court has awarded Natera a 30% ongoing royalty on post-injunction revenues related to its MRD patents, building on a previous 20.5% royalty for pre-injunction sales. The court also upheld the validity and infringement findings of Natera's patents against ArcherDx and Invitae, strengthening Natera's intellectual property portfolio. Natera's shares saw a slight increase in premarket trading following the announcement, and the company is expected to release its next financial update in M", "sentiment_score": 0.642544, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "alpha_vantage", "title": "Natera Says Court Orders 30% Royalties From ArcherDx, Invitae on Post-Injunction Sales", "url": "https://www.marketscreener.com/news/natera-says-court-orders-30-royalties-from-archerdx-invitae-on-post-injunction-sales-ce7e50dbd189f726", "date": "2026-04-09", "summary": "A court has ordered ArcherDx and Invitae to pay a 30% royalty to Natera for post-injunction sales. This decision follows a patent dispute and is expected to impact the financial performance of the involved diagnostic companies. Natera, a diagnostics company focusing on women's health, oncology, and organ health, will receive these royalties.", "sentiment_score": 0.417348, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera wins 30% ongoing royalty in patent case against Invitae By Investing.com", "url": "https://in.investing.com/news/company-news/natera-wins-30-ongoing-royalty-in-patent-case-against-invitae-93CH-5329628", "date": "2026-04-09", "summary": "Natera Inc. has won a court decision granting it a 30% ongoing royalty on post-injunction revenues from certain minimal residual disease-related product sales by ArcherDx and Invitae. This ruling follows an earlier injunction and upholds the validity of Natera's MRD patents. The company, trading at $210.83 with a market capitalization of $29.88 billion, has seen its stock valuation positively influenced, with analysts revising earnings upwards despite an InvestingPro analysis suggesting it is cu", "sentiment_score": 0.48405, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.572, "confidence": 0.57 } }, { "source": "alpha_vantage", "title": "Natera (NASDAQ: NTRA) chair exercises options, uses shares for taxes", "url": "https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-69aa6881ce05.html", "date": "2026-04-09", "summary": "Matthew Rabinowitz, Executive Chairman of Natera (NASDAQ: NTRA), exercised stock options to acquire 58,292 shares at $9.59 each and subsequently had 27,610 shares withheld at $204.87 for tax obligations. Following these transactions, Rabinowitz directly holds 2,383,162 shares and indirectly holds 5,000 shares through his spouse. The filing also details key figures like exercise price, tax-withholding price, and his holdings after the transactions.", "sentiment_score": 0.005419, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "NTRA Financials: Revenue Breakdown, Margins & Competitor Comparison", "url": "https://intellectia.ai/en/stock/NTRA/financials", "date": "2026-04-08", "summary": "This article provides a financial analysis of Natera Inc (NTRA), detailing its revenue breakdown, profit margins, and a comparison with competitors. Natera primarily generates revenue from insurance carriers, holding a significant market share with a $29.66 billion market capitalization. It highlights the company's gross margin, operating margin, and net margin, alongside its Return on Equity, and benchmarks its gross margin against industry rivals IQV and UTHR.", "sentiment_score": 0.101302, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera Inc. (NTRA): Upside Potential Pulls Billionaire Stan Druckenmiller", "url": "https://www.insidermonkey.com/blog/natera-inc-ntra-upside-potential-pulls-billionaire-stan-druckenmiller-1733871/?amp=1", "date": "2026-04-08", "summary": "Billionaire Stan Druckenmiller's Duquesne Capital holds a significant stake in Natera, Inc. (NTRA), increasing its position in the company which is recognized for its molecular residual disease test, Signatera. Natera's recent achievement of positive cash inflow in 2025 has shifted the narrative among institutional investors, mitigating concerns about cash burn and potential dilution risks. The article highlights the strong growth of Signatera and Natera's growing integration into clinical guide", "sentiment_score": 0.487306, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform", "url": "https://www.businesswire.com/news/home/20260407837545/en/20-Abstracts-at-AACR-Highlight-Scale-Innovation-and-Clinical-Impact-of-Nateras-Oncology-Platform", "date": "2026-04-08", "summary": "Natera, Inc. announced that 20 abstracts, including two oral presentations, featuring data generated using its technologies will be presented at the 2026 AACR Annual Meeting. These presentations highlight advances in AI-driven virtual genomics, Signatera™-guided treatment monitoring, and the ongoing expansion of their molecular residual disease (MRD) and other capabilities. The research demonstrates Natera's innovative approaches to provide more precise and data-driven solutions in cancer care.", "sentiment_score": 0.478242, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.812, "confidence": 0.81 } }, { "source": "alpha_vantage", "title": "Citi Maintains Natera(NTRA.US) With Buy Rating, Maintains Target Price $300", "url": "https://www.moomoo.com/news/post/67968518/citi-maintains-natera-ntraus-with-buy-rating-maintains-target-price", "date": "2026-04-08", "summary": "Citi has reiterated its Buy rating for Natera (NTRA.US) and maintained a target price of $300. This continued endorsement suggests the firm sees strong potential for the company's performance, indicating a positive outlook on its valuation and business prospects.", "sentiment_score": 0.432789, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform", "url": "https://www.biospace.com/press-releases/20-abstracts-at-aacr-highlight-scale-innovation-and-clinical-impact-of-nateras-oncology-platform", "date": "2026-04-07", "summary": "Natera, Inc. announced that 20 abstracts, including two oral presentations, featuring data from its oncology technologies will be presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. These presentations highlight the scale, innovation, and clinical impact of Natera's oncology platform, including advancements in AI-driven virtual genomics, Signatera™-guided treatment monitoring, and expansion of molecular residual disease (MRD) capabilities. Key research areas inc", "sentiment_score": 0.405966, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.812, "confidence": 0.81 } }, { "source": "alpha_vantage", "title": "Natera (NTRA) Gets 90-Day Catalyst Watch from Citi and Maintains Buy Rating", "url": "https://www.gurufocus.com/news/8777278/natera-ntra-gets-90day-catalyst-watch-from-citi-and-maintains-buy-rating?mobile=true", "date": "2026-04-07", "summary": "Citi has placed Natera (NTRA) on a \"90-day catalyst watch\" and reaffirmed its Buy rating with a $300 price target, anticipating strong financial momentum despite a recent stock pullback. Natera, a diagnostic and research company, shows robust revenue growth and a strong balance sheet but faces challenges in profitability and has high institutional ownership alongside insider selling. The company's performance, particularly upcoming earnings, will be key to its future trajectory, requiring invest", "sentiment_score": 0.443638, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "56,665 Shares in Natera, Inc. $NTRA Purchased by Robinhood Asset Management LLC", "url": "https://www.marketbeat.com/instant-alerts/filing-56665-shares-in-natera-inc-ntra-purchased-by-robinhood-asset-management-llc-2026-04-07/", "date": "2026-04-07", "summary": "Robinhood Asset Management LLC recently acquired 56,665 shares of Natera, Inc. (NTRA) in the fourth quarter, a stake valued at approximately $12.98 million, making it their 23rd largest holding. While Natera exceeded Q4 earnings and revenue estimates, it remains unprofitable, and insiders have sold a significant number of shares recently. Despite high institutional ownership, analysts have a \"Moderate Buy\" consensus rating with an average target price of $253.47.", "sentiment_score": 0.182326, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.572, "confidence": 0.57 } }, { "source": "alpha_vantage", "title": "Evercore Maintains Natera(NTRA.US) With Buy Rating, Cuts Target Price to $250", "url": "https://www.moomoo.com/news/post/67925664/evercore-maintains-natera-ntraus-with-buy-rating-cuts-target-price", "date": "2026-04-06", "summary": "Evercore has reiterated its Buy rating on Natera (NTRA.US) stock while simultaneously lowering its price target to $250. This adjustment indicates a continued positive outlook on the company despite potential short-term headwinds or revised growth expectations, reflected in the reduced target price. Investors will likely be watching Natera's performance closely in light of Evercore's maintained confidence but recalibrated valuation.", "sentiment_score": 0.039766, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Natera president sells $606,899 in NTRA stock", "url": "https://www.investing.com/news/insider-trading-news/natera-president-sells-606899-in-ntra-stock-93CH-4597490", "date": "2026-04-04", "summary": "Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., sold 3,000 shares of NTRA stock for approximately $606,899 on April 1, 2026. These sales, executed under a pre-arranged trading plan, occurred at prices ranging from $201.32 to $203.31 per share. This insider transaction comes as Natera stock trades above its InvestingPro Fair Value, suggesting potential overvaluation, though the company recently announced advancements in medical testing and an expanded board.", "sentiment_score": 0.091067, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 3,000 Shares of Stock", "url": "https://www.marketbeat.com/instant-alerts/natera-nasdaqntra-insider-solomon-moshkevich-sells-3000-shares-of-stock-2026-04-03/", "date": "2026-04-04", "summary": "Natera insider Solomon Moshkevich recently sold 3,000 shares of the company's stock for over $600,000, reducing his stake by 1.99%. This transaction is part of a pattern of ongoing insider disposals by Moshkevich, who has made several other significant sales since January. Despite these insider sales, Natera recently exceeded quarterly EPS and revenue estimates and holds a \"Moderate Buy\" consensus analyst rating with a target price of $253.47.", "sentiment_score": -0.209614, "sentiment_label": "Somewhat-Bearish", "relevance_score": 0.960031, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Natera president sells $606,899 in NTRA stock", "url": "https://m.investing.com/news/insider-trading-news/natera-president-sells-606899-in-ntra-stock-93CH-4597490?ampMode=1", "date": "2026-04-04", "summary": "Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NTRA), sold 3,000 shares of company stock for approximately $606,899 on April 1, 2026. These sales were executed under a pre-arranged trading plan, and Moshkevich still directly owns 147,882 shares. The article also touches on recent company developments, including new genetic tests and board expansion, and an adjusted price target by Morgan Stanley.", "sentiment_score": 0.121931, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera SEC. sold $1.7m in NTRA stock", "url": "https://www.investing.com/news/insider-trading-news/natera-sec-sold-17m-in-ntra-stock-93CH-4597491", "date": "2026-04-04", "summary": "Daniel Rabinowitz, SEC. and Chief Legal Officer of Natera, Inc. (NASDAQ:NTRA), sold 8,400 shares of common stock totaling $1.7 million on April 1, 2026. This insider sale followed a 55% surge in Natera's stock over the past year, placing it among InvestingPro's most overvalued companies. The company has recently launched new genomics tests and seen a price target adjustment from Morgan Stanley.", "sentiment_score": 0.07635, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera (NTRA) president sells 3,000 shares under Rule 10b5-1 plan", "url": "https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-7cfdbe66df68.html", "date": "2026-04-04", "summary": "Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NTRA), sold 3,000 shares of common stock on April 1, 2026, through an open-market transaction. These sales were pre-arranged under a Rule 10b5-1 trading plan adopted on November 26, 2024. Following these transactions, Moshkevich directly holds 147,882 shares of Natera.", "sentiment_score": -0.268909, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Natera (NASDAQ: NTRA) legal chief sells 8,400 shares in preset 10b5-1 plan", "url": "https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-0e25ff27fe5c.html", "date": "2026-04-04", "summary": "Natera's Secretary and Chief Legal Officer, Daniel Rabinowitz, sold 8,400 shares of the company's common stock on April 1, 2026. The sales were conducted through a pre-arranged Rule 10b5-1 trading plan at weighted average prices between $200.47 and $205.50 per share. Following these transactions, Rabinowitz still holds 224,885 shares of Natera common stock.", "sentiment_score": 0.036068, "sentiment_label": "Neutral", "relevance_score": 0.342534, "sentiment": { "label": "positive", "score": 0.402, "confidence": 0.4 } }, { "source": "alpha_vantage", "title": "Natera SEC. sold $1.7m in NTRA stock", "url": "https://m.investing.com/news/insider-trading-news/natera-sec-sold-17m-in-ntra-stock-93CH-4597491?ampMode=1", "date": "2026-04-04", "summary": "Daniel Rabinowitz, SEC. AND CHIEF LEGAL OFFICER of Natera, Inc. (NASDAQ:NTRA), sold 8,400 shares of common stock for $1.7 million on April 1, 2026, through a Rule 10b5-1 trading plan. This sale occurred as Natera's stock surged 55% over the past year. In other news, Natera launched Zenith genomics and its Signatera test showed promising results in cancer studies.", "sentiment_score": -0.203101, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera (NTRA) chair exercises 41,708 options, now holds 2.35M shares", "url": "https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-2cb7102ee209.html", "date": "2026-04-02", "summary": "Matthew Rabinowitz, Executive Chairman of Natera (NTRA), exercised 41,708 stock options at a strike price of $9.59 per share. This transaction increased his direct holdings to 2,352,480 shares of Natera Common Stock, with an additional 58,292 stock options and 5,000 indirect shares through his spouse. The filing confirms no shares were sold and the options were fully exercisable.", "sentiment_score": 0.029921, "sentiment_label": "Neutral", "relevance_score": 0.343423, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Natera Expands Board, Appoints Eric Rubin as Director", "url": "https://www.tipranks.com/news/company-announcements/natera-expands-board-appoints-eric-rubin-as-director", "date": "2026-04-01", "summary": "Natera has expanded its Board of Directors from ten to eleven members, appointing Eric Rubin as an independent Class I director effective March 26, 2026. Dr. Rubin will also join the Nominating, Corporate Governance and Compliance Committee and will receive standard director compensation. This move emphasizes Natera's commitment to independent oversight and regulatory compliance, with Dr. Rubin having no related-party ties to the company.", "sentiment_score": 0.281888, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.103, "confidence": 0.1 } }, { "source": "alpha_vantage", "title": "Eric Rubin appointed to Natera board as Class I director", "url": "https://www.tradingview.com/news/tradingview:cf61fa6d2a1b1:0-eric-rubin-appointed-to-natera-board-as-class-i-director/", "date": "2026-04-01", "summary": "Natera has appointed Eric Rubin to its Board of Directors as a Class I director, effective March 26, 2026. This appointment increased the board's size from ten to eleven members, with Rubin also joining the Nominating, Corporate Governance and Compliance Committee. He will receive standard cash and equity compensation for non-employee directors, with his initial equity award vesting over three years.", "sentiment_score": 0.382462, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Eric Rubin joins Natera (NASDAQ: NTRA) board as independent director", "url": "https://www.stocktitan.net/sec-filings/NTRA/8-k-natera-inc-reports-material-event-10e242e4f351.html", "date": "2026-04-01", "summary": "Natera, Inc. has expanded its Board of Directors to eleven members by appointing Eric Rubin as a Class I independent director, effective March 26, 2026. Dr. Rubin will serve on the Nominating, Corporate Governance and Compliance Committee and will receive standard cash and equity compensation, with his initial equity award vesting in three equal installments. An Indemnification Agreement has also been put in place for his service to the company.", "sentiment_score": 0.221167, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "J. Safra Sarasin Holding AG Makes New Investment in Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-j-safra-sarasin-holding-ag-makes-new-investment-in-natera-inc-ntra-2026-04-01/", "date": "2026-04-01", "summary": "J. Safra Sarasin Holding AG recently acquired a new stake of 12,331 shares in Natera, Inc. (NASDAQ:NTRA), valued at approximately $2.83 million, during the fourth quarter. This move aligns with other institutional investors, contributing to Natera's 99.90% institutional ownership. Despite beating Q4 earnings estimates with $0.35 EPS and $665.5 million in revenue, the company remains unprofitable with significant insider selling recorded, while analysts hold a \"Moderate Buy\" consensus.", "sentiment_score": 0.229029, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Signatera Data in Older Breast Cancer Patients Could Be A Game Changer For Natera (NTRA)", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/signatera-data-in-older-breast-cancer-patients-could-be-a-ga", "date": "2026-04-01", "summary": "Natera's Signatera molecular residual disease test has shown promising results in a new study, allowing older women with early-stage ER+/HER2- breast cancer to opt for primary endocrine therapy over surgery. This development could reshape Natera's investment narrative by reinforcing Signatera's clinical utility and potentially influencing future reimbursement decisions for various oncology indications. Despite optimistic forecasts, analysts remain cautious about the company's path to profitabili", "sentiment_score": 0.433586, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "alpha_vantage", "title": "Natera, Inc. $NTRA Shares Sold by Allspring Global Investments Holdings LLC", "url": "https://www.marketbeat.com/instant-alerts/filing-natera-inc-ntra-shares-sold-by-allspring-global-investments-holdings-llc-2026-04-01/", "date": "2026-04-01", "summary": "Allspring Global Investments Holdings LLC significantly reduced its stake in Natera, Inc. (NTRA) by 4.4% in the fourth quarter, selling 20,896 shares and retaining 454,498 shares. This comes amidst heavy insider selling, including transactions by CEO Steven Chapman and another insider, totaling over $74.1 million in the last quarter, though insiders still hold 5.63% of the stock. Despite this, institutional investors collectively own 99.90% of Natera's stock, and the company reported an EPS beat", "sentiment_score": 0.067698, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Natera's Signatera Data Suggests Select Breast Cancer Patients Could Skip Surgery", "url": "https://www.benzinga.com/news/health-care/26/03/51576065/nateras-signatera-data-suggests-select-breast-cancer-patients-could-skip-surgery", "date": "2026-03-31", "summary": "Natera's Signatera molecular residual disease (MRD) test has shown promising results, indicating that select breast cancer patients could potentially avoid surgery. A study published in Clinical Cancer Research demonstrated Signatera's ability to identify older women with early-stage ER+/HER2- breast cancer who can be effectively managed with primary endocrine therapy. The study highlights Signatera's strong predictive accuracy and early-detection capabilities, supporting its utility for non-sur", "sentiment_score": 0.023866, "sentiment_label": "Neutral", "relevance_score": 0.315756, "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "alpha_vantage", "title": "Avoiding Lag: Real-Time Signals in (NTRA) Movement", "url": "https://news.stocktradersdaily.com/news_release/12/Avoiding_Lag:_Real-Time_Signals_in_NTRA_Movement_033126033202_1774985522.html", "date": "2026-03-31", "summary": "This article provides a detailed analysis of Natera Inc. (NASDAQ: NTRA) movement, highlighting weak near-term sentiment despite long-term strength. It outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis emphasizes a strong risk-reward setup, real-time signals, and multi-timeframe insights for traders.", "sentiment_score": 0.190595, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.586, "confidence": 0.59 } }, { "source": "alpha_vantage", "title": "Natera, Inc. $NTRA Shares Sold by Zevenbergen Capital Investments LLC", "url": "https://www.marketbeat.com/instant-alerts/filing-natera-inc-ntra-shares-sold-by-zevenbergen-capital-investments-llc-2026-03-31/", "date": "2026-03-31", "summary": "Zevenbergen Capital Investments LLC has reduced its stake in Natera, Inc. by 18% in the fourth quarter, selling 70,994 shares, although the stock still constitutes 1.6% of its portfolio. Despite this, other institutional investors have shown increased interest, while significant insider selling, including by the CFO and CEO, has occurred. Analysts maintain a \"Moderate Buy\" consensus for Natera, with an average price target of $253.47, following strong quarterly results that beat expectations.", "sentiment_score": 0.04746, "sentiment_label": "Neutral", "relevance_score": 0.328701, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Blood test helped some women over 70 with breast cancer avoid surgery", "url": "https://www.stocktitan.net/news/NTRA/signatera-tm-mrd-identifies-breast-cancer-patients-who-can-forgo-ro16r8unwe94.html", "date": "2026-03-31", "summary": "A new study published in Clinical Cancer Research indicates that Natera's Signatera™ molecular residual disease (MRD) test can identify older women with early-stage ER+/HER2- breast cancer who can safely forgo surgery and be managed with primary endocrine therapy. The study found that 100% of patients who were MRD-negative at baseline remained progression-free. These findings suggest that Signatera can help inform treatment decisions, potentially reducing the need for surgery in a vulnerable pat", "sentiment_score": 0.492119, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.765, "confidence": 0.77 } }, { "source": "alpha_vantage", "title": "Natera Inc (NTRA) Shares Down 6.88% on Mar 30", "url": "https://www.gurufocus.com/news/8756834/natera-inc-ntra-shares-down-688-on-mar-30?mobile=true", "date": "2026-03-30", "summary": "Natera Inc (NTRA) shares dropped 6.88% on March 30, closing at $182.65. Wall Street analysts project an average price target of $253.56, indicating a 38.82% upside, with an \"Outperform\" consensus recommendation. GuruFocus estimates a fair value of $213.11, suggesting a 16.68% upside from the current price.", "sentiment_score": -0.381881, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Dakota Wealth Management Buys Shares of 5,921 Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-dakota-wealth-management-buys-shares-of-5921-natera-inc-ntra-2026-03-29/", "date": "2026-03-29", "summary": "Dakota Wealth Management purchased 5,921 shares of Natera, Inc. (NASDAQ:NTRA), valued at approximately $1.36 million, in the fourth quarter, joining other institutional investors increasing their stake. Despite strong institutional ownership (99.90%), company insiders, including CEO Steven Leonard Chapman, have recently sold a significant number of shares. Natera exceeded Q4 earnings expectations with $0.35 EPS against an estimated -$0.46, and analysts maintain a \"Moderate Buy\" rating with an av", "sentiment_score": 0.298778, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.66, "confidence": 0.66 } }, { "source": "alpha_vantage", "title": "DAVENPORT & Co LLC Takes Position in Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-davenport-co-llc-takes-position-in-natera-inc-ntra-2026-03-28/", "date": "2026-03-28", "summary": "DAVENPORT & Co LLC has initiated a new position in Natera, Inc. (NASDAQ: NTRA) during Q4, acquiring 14,032 shares valued at approximately $3.215 million. While institutional investors hold a significant portion of the stock, recent insider activity shows sales by CEO Steven Leonard Chapman and other insiders totaling over $74 million in the last 90 days. Natera recently beat quarterly earnings and revenue estimates and holds a \"Moderate Buy\" consensus rating from analysts with an average price t", "sentiment_score": 0.342805, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera, Inc. $NTRA Shares Sold by Assenagon Asset Management S.A.", "url": "https://www.marketbeat.com/instant-alerts/filing-natera-inc-ntra-shares-sold-by-assenagon-asset-management-sa-2026-03-28/", "date": "2026-03-28", "summary": "Assenagon Asset Management S.A. significantly reduced its stake in Natera, Inc. (NASDAQ:NTRA) by 85.5% in the fourth quarter, selling over 261,000 shares. Despite Natera reporting a surprise earnings beat with $0.35 EPS against a -$0.46 consensus, and revenue exceeding estimates, the company still has negative margins and analysts anticipate a negative EPS for the current year. Insider selling has also been observed, with major officers offloading shares, while institutional investors maintain a", "sentiment_score": -0.142581, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.572, "confidence": 0.57 } }, { "source": "alpha_vantage", "title": "A Look At Natera (NTRA) Valuation After Recent Share Price Weakness", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/a-look-at-natera-ntra-valuation-after-recent-share-price-wea", "date": "2026-03-28", "summary": "Natera (NTRA) has experienced recent share price weakness, though its long-term shareholder returns remain strong. Despite the pullback, the company is considered undervalued by some intrinsic estimates and analyst price targets, with a fair value pegged at $260.65 per share due to growth in molecular diagnostics. However, its current P/S ratio is above the industry average, suggesting less room for error if growth falters.", "sentiment_score": 0.327736, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.153, "confidence": 0.15 } }, { "source": "alpha_vantage", "title": "Natera Inc (NTRA) Shares Down 4.14% on Mar 27", "url": "https://www.gurufocus.com/news/8750024/natera-inc-ntra-shares-down-414-on-mar-27", "date": "2026-03-28", "summary": "Shares of Natera Inc (NTRA) dropped 4.14% on March 27, reaching an intraday low of $187.86 before settling at $188.02. This stock price is 26.66% below its 52-week high and 49.96% above its 52-week low. Wall Street analysts have an average target price of $253.56 for NTRA, indicating an \"Outperform\" status and a potential upside of 34.86%.", "sentiment_score": -0.223504, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics Shares Plummet, What You Need To Know", "url": "https://www.tradingview.com/news/stockstory:97d4478af094b:0-elanco-tandem-diabetes-fortrea-natera-and-myriad-genetics-shares-plummet-what-you-need-to-know/", "date": "2026-03-27", "summary": "Several stocks including Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics experienced significant drops in the afternoon trading session. This market downturn is attributed to rising uncertainty from the U.S.-Iran conflict and policy deadlines set by the Trump administration, leading to a dip in consumer confidence. Despite the broader market reaction, the article highlights potential buying opportunities in these quality stocks given that markets often overreact to news.", "sentiment_score": -0.246363, "sentiment_label": "Somewhat-Bearish", "relevance_score": 0.939865, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Vanguard disaggregates holdings; reports 0 shares for Natera (NTRA)", "url": "https://www.stocktitan.net/sec-filings/NTRA/schedule-13g-a-natera-inc-amended-passive-investment-disclosure-b9cf16bd8fd9.html", "date": "2026-03-27", "summary": "Vanguard has reported 0 beneficial shares owned in Natera (NTRA) following an internal realignment effective January 12, 2026. This change means that certain Vanguard subsidiaries will now report their holdings separately, although their investment strategies remain unchanged. The filing indicates that The Vanguard Group itself no longer holds beneficial ownership over securities held by these disaggregated subsidiaries.", "sentiment_score": 0.019496, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Wealth Enhancement Advisory Services LLC Has $11.48 Million Stock Position in Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-wealth-enhancement-advisory-services-llc-has-1148-million-stock-position-in-natera-inc-ntra-2026-03-27/", "date": "2026-03-27", "summary": "Wealth Enhancement Advisory Services LLC increased its stake in Natera, Inc. (NASDAQ:NTRA) by 25.9% to holdings worth $11.48 million, contributing to institutional investors owning 99.90% of the company. Natera surpassed Q4 earnings and revenue estimates but remains unprofitable with negative margins. Despite significant insider selling totaling $74.09 million in the last 90 days, analysts maintain a \"Moderate Buy\" rating with an average price target of $253.47.", "sentiment_score": 0.120583, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "alpha_vantage", "title": "Is It Time To Reassess Natera (NTRA) After Its Recent Share Price Pullback", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/is-it-time-to-reassess-natera-ntra-after-its-recent-share-pr", "date": "2026-03-26", "summary": "This article examines Natera (NTRA) after a recent share price pullback, noting its strong 1-year and 3-year returns despite a current decline. Using two valuation methods, a Discounted Cash Flow (DCF) analysis suggests Natera is 37.8% undervalued, while a Price-to-Sales (P/S) ratio comparison indicates it might be overvalued relative to its Fair Ratio. The article encourages investors to use \"Narratives\" on the Simply Wall St platform to form their own valuation based on differing assumptions.", "sentiment_score": 0.266793, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "If You Invested $1000 In Natera Stock 10 Years Ago, You Would Have This Much Today", "url": "https://www.sahmcapital.com/news/content/if-you-invested-1000-in-natera-stock-10-years-ago-you-would-have-this-much-today-2026-03-25", "date": "2026-03-25", "summary": "Natera (NTRA) has significantly outperformed the market over the last decade, with an average annual return of 36.62%. An initial investment of $1000 in Natera stock 10 years ago would now be worth $22,576.05. This highlights the powerful effect of compounded returns on investment growth over time.", "sentiment_score": 0.510236, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera (NTRA) Launches Zenith Genomic Assay", "url": "https://www.insidermonkey.com/blog/natera-ntra-launches-zenith-genomic-assay-1723130/", "date": "2026-03-24", "summary": "Natera, Inc. (NASDAQ: NTRA) has commercially launched Zenith, a whole-genome sequencing assay designed to improve the diagnosis of rare genetic conditions and shorten the diagnostic journey for millions of Americans. This new clinical tool aims to address the significant unmet needs and economic burden associated with rare diseases. The launch follows a recent price target reduction for Natera by Morgan Stanley, though the firm maintained an Overweight rating.", "sentiment_score": 0.20121, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera, Inc. (NASDAQ:NTRA) Given Consensus Recommendation of \"Moderate Buy\" by Brokerages", "url": "https://www.marketbeat.com/instant-alerts/natera-inc-nasdaqntra-given-consensus-recommendation-of-moderate-buy-by-brokerages-2026-03-24/", "date": "2026-03-24", "summary": "Eighteen brokerages have given Natera, Inc. (NASDAQ:NTRA) a \"Moderate Buy\" consensus recommendation, with an average 12-month price target of $253.47. Despite beating Q4 earnings and revenue estimates, the company remains unprofitable with negative net margin and return on equity. Recent insider selling by the CFO and CEO has been noted, although institutional investors have increased their holdings.", "sentiment_score": 0.107166, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera Inc (NTRA) Stock Price Up 2.86% on Mar 23", "url": "https://www.gurufocus.com/news/8736353/natera-inc-ntra-stock-price-up-286-on-mar-23", "date": "2026-03-23", "summary": "Shares of Natera Inc (NTRA) rose by 2.86% in mid-day trading on March 23, closing at $200.87. Wall Street analysts forecast an average target price of $253.56, indicating an upside of 26.23%, with an \"Outperform\" recommendation. GuruFocus estimates a one-year GF Value of $213.32 for NTRA, suggesting a 6.2% upside.", "sentiment_score": 0.333572, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera co-founder Jonathan Sheena sells shares worth $908,301", "url": "https://www.investing.com/news/insider-trading-news/natera-cofounder-jonathan-sheena-sells-shares-worth-908301-93CH-4574014", "date": "2026-03-21", "summary": "Natera co-founder Jonathan Sheena sold 5,360 shares of the company's common stock for a total of $908,301 across two transactions in March 2026. Despite a year-to-date decline, Natera's stock gained 4% in the week of the sales and analysts maintain a bullish outlook with price targets up to $300. The company's market capitalization stands at $27.81 billion, though InvestingPro analysis suggests the stock is currently overvalued.", "sentiment_score": 0.004743, "sentiment_label": "Neutral", "relevance_score": 0.335206, "sentiment": { "label": "positive", "score": 0.477, "confidence": 0.48 } }, { "source": "alpha_vantage", "title": "Natera (NASDAQ: NTRA) co-founder reports 4,570-share planned stock sale", "url": "https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-fc5307cf2697.html", "date": "2026-03-21", "summary": "Natera's co-founder, Jonathan Sheena, reported planned sales of 4,570 shares of common stock on March 18 and March 20, 2026. The sales were executed at prices ranging from approximately $196 to $201 per share under pre-arranged Rule 10b5-1 trading plans adopted in June and December 2024. These transactions included both direct holdings and shares held by Caraluna 1 Trust and Caraluna 2 Trust, with Sheena disclaiming beneficial ownership of the trust-held shares.", "sentiment_score": -0.248865, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41963611", "title": "Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 study.", "authors": "Venturini J et al.", "journal": "NPJ precision oncology", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41963611/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41962310", "title": "New prognostic and predictive scoring systems for colorectal cancer liver metastases.", "authors": "Salvà F et al.", "journal": "ESMO open", "date": "2026 Apr 9", "url": "https://pubmed.ncbi.nlm.nih.gov/41962310/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41956543", "title": "HosTIL territory: mapping the landscape of toxicity in TIL therapy.", "authors": "Woodford R et al.", "journal": "Journal for immunotherapy of cancer", "date": "2026 Apr 9", "url": "https://pubmed.ncbi.nlm.nih.gov/41956543/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41955548", "title": "Bespoke Circulating Tumor DNA Testing for Diagnostic Resolution, Disease Surveillance, and Treatment Monitoring in Hepatopancreatobiliary Malignancies: A Real-World Experience.", "authors": "Abidoye O et al.", "journal": "JCO precision oncology", "date": "2026-04-12", "url": "https://pubmed.ncbi.nlm.nih.gov/41955548/", "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "pubmed", "pmid": "41954938", "title": "Survival and Treatment Patterns in Stage III Inflammatory and Noninflammatory Breast Cancer.", "authors": "Leone JP et al.", "journal": "JAMA network open", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41954938/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41954928", "title": "Colorectal Cancer and Mortality Risk Among Older Adults With vs Without Adenoma on Prior Colonoscopy.", "authors": "Gupta S et al.", "journal": "JAMA", "date": "2026 Apr 9", "url": "https://pubmed.ncbi.nlm.nih.gov/41954928/", "sentiment": { "label": "negative", "score": -0.758, "confidence": 0.76 } }, { "source": "pubmed", "pmid": "41953531", "title": "Characterizing therapeutic target antigen expression in anaplastic carcinoma of the ovary.", "authors": "Sullivan MW et al.", "journal": "Gynecologic oncology reports", "date": "2026-04-12", "url": "https://pubmed.ncbi.nlm.nih.gov/41953531/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41953135", "title": "Concordance between genome-wide cfDNA screening and diagnostic test results for large copy-number variants: a multi-site study from the Global Expanded NIPT Consortium.", "authors": "Soster E et al.", "journal": "Frontiers in genetics", "date": "2026-04-12", "url": "https://pubmed.ncbi.nlm.nih.gov/41953135/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41950572", "title": "From clusters to clinic: An 8-gene signature combined with mucinous component stratifies benefit of anti-CTLA-4 addition to anti-PD-1 in dMMR/MSI-H metastatic colorectal cancer.", "authors": "Ambrosini M et al.", "journal": "European journal of cancer (Oxford, England : 1990)", "date": "2026 Apr 5", "url": "https://pubmed.ncbi.nlm.nih.gov/41950572/", "sentiment": { "label": "negative", "score": -0.34, "confidence": 0.34 } }, { "source": "pubmed", "pmid": "41945184", "title": "The LIFT UP study: feasibility of systematically identifying and addressing resource needs in those with metastatic breast cancer.", "authors": "Fadelu TA et al.", "journal": "Breast cancer research and treatment", "date": "2026 Apr 7", "url": "https://pubmed.ncbi.nlm.nih.gov/41945184/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41940628", "title": "SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC.", "authors": "Peters S et al.", "journal": "Future oncology (London, England)", "date": "2026-04-12", "url": "https://pubmed.ncbi.nlm.nih.gov/41940628/", "sentiment": { "label": "positive", "score": 0.44, "confidence": 0.44 } }, { "source": "pubmed", "pmid": "41939727", "title": "Remote digital intervention targeting heart failure medical therapy: a randomized controlled trial.", "authors": "DeVore AD et al.", "journal": "Lancet regional health. Americas", "date": "2026-04-12", "url": "https://pubmed.ncbi.nlm.nih.gov/41939727/", "sentiment": { "label": "positive", "score": 0.226, "confidence": 0.23 } }, { "source": "pubmed", "pmid": "41933595", "title": "Safety profile of KRAS G12C inhibitors combined with thoracic radiation therapy.", "authors": "Miller DG et al.", "journal": "Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41933595/", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "pubmed", "pmid": "41932032", "title": "Translating ctDNA into cutaneous melanoma care: An international expert survey.", "authors": "Geidel G et al.", "journal": "European journal of cancer (Oxford, England : 1990)", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41932032/", "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "pubmed", "pmid": "41931740", "title": "Circulating Tumor DNA Monitoring in Peptide Receptor Radionuclide Therapy-Treated Patients With Gastroenteropancreatic Neuroendocrine Tumors.", "authors": "Bogdani C et al.", "journal": "JCO precision oncology", "date": "2026-04-12", "url": "https://pubmed.ncbi.nlm.nih.gov/41931740/", "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "pubmed", "pmid": "41926089", "title": "Clonal Hematopoiesis and Risk of Trastuzumab-Related Cardiotoxic Effects.", "authors": "Park CS et al.", "journal": "JAMA oncology", "date": "2026 Apr 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41926089/", "sentiment": { "label": "negative", "score": -0.273, "confidence": 0.27 } }, { "source": "pubmed", "pmid": "41924551", "title": "Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.", "authors": "Eslinger C et al.", "journal": "Drug design, development and therapy", "date": "2026-04-12", "url": "https://pubmed.ncbi.nlm.nih.gov/41924551/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41922555", "title": "A Mobile Exhibition to Advance Cancer Prevention Awareness: A Cross-Sectional Evaluation Using the RE-AIM Framework.", "authors": "Fey T et al.", "journal": "Journal of cancer education : the official journal of the American Association for Cancer Education", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41922555/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41919756", "title": "How genetic counselors in North America describe their professional identity.", "authors": "Schwartz L et al.", "journal": "Journal of genetic counseling", "date": "2026-04-12", "url": "https://pubmed.ncbi.nlm.nih.gov/41919756/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41919242", "title": "Testing for hereditary cancer genes in men: a missed opportunity for cancer prevention.", "authors": "Szmyd C et al.", "journal": "Frontiers in oncology", "date": "2026-04-12", "url": "https://pubmed.ncbi.nlm.nih.gov/41919242/", "sentiment": { "label": "negative", "score": -0.848, "confidence": 0.85 } }, { "source": "pubmed", "pmid": "41917040", "title": "Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER(+) HER2(-) locally-advanced or metastatic breast cancer.", "authors": "Liang J et al.", "journal": "Nature communications", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41917040/", "sentiment": { "label": "negative", "score": -1.0, "confidence": 1.0 } }, { "source": "pubmed", "pmid": "41912809", "title": "Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.", "authors": "Wainberg ZA et al.", "journal": "Nature medicine", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41912809/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41910021", "title": "A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.", "authors": "Johnson ML et al.", "journal": "Future oncology (London, England)", "date": "2026-04-12", "url": "https://pubmed.ncbi.nlm.nih.gov/41910021/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41908612", "title": "Three People With Recurrent Nephrolithiasis and Heterozygous ABCC6 Mutations.", "authors": "Farrell D et al.", "journal": "Kidney medicine", "date": "2026-04-12", "url": "https://pubmed.ncbi.nlm.nih.gov/41908612/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41904847", "title": "Evaluating the safety and efficacy of chemotherapy in patients with relapsed small cell lung cancer combined with allopurinol and MycoPhenolate (CLAMP).", "authors": "Knapp B et al.", "journal": "Lung cancer (Amsterdam, Netherlands)", "date": "2026-04-12", "url": "https://pubmed.ncbi.nlm.nih.gov/41904847/", "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "pubmed", "pmid": "41903996", "title": "Utility of Circulating Tumor DNA-Based Liquid Biopsies in Patients with Cancer Receiving Immunotherapy.", "authors": "Teixeira MF et al.", "journal": "Surgical oncology clinics of North America", "date": "2026-04-12", "url": "https://pubmed.ncbi.nlm.nih.gov/41903996/", "sentiment": { "label": "negative", "score": -0.791, "confidence": 0.79 } }, { "source": "pubmed", "pmid": "41903855", "title": "Organ-specific differences in the epidemiology of cytomegalovirus infections in high-risk (CMV D+R-) solid organ transplant recipients with prolonged follow-up: a ten-year experience.", "authors": "Heldman MR et al.", "journal": "American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41903855/", "sentiment": { "label": "positive", "score": 0.153, "confidence": 0.15 } }, { "source": "pubmed", "pmid": "41903539", "title": "Advancing precision health discovery in a genetically diverse health system.", "authors": "Haas R et al.", "journal": "Cell", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41903539/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41896510", "title": "ASO Author Reflections: New Insights for Personalized HIPEC Strategies in Colorectal Cancer Peritoneal Metastases.", "authors": "Gupta P et al.", "journal": "Annals of surgical oncology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41896510/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41895280", "title": "Cancer type-specific variation in patterns of driver alterations across 50,000 tumors.", "authors": "Bandlamudi C et al.", "journal": "Cancer cell", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41895280/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41891361", "title": "Disparities in Genetic Testing: Evaluation of Reproductive Carrier Screening in the United States.", "authors": "Parmar S et al.", "journal": "Genetics in medicine : official journal of the American College of Medical Genetics", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41891361/", "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "pubmed", "pmid": "41883872", "title": "Molecular complete response to the RIN protocol (regorafenib, ipilimumab, and nivolumab) in a patient with advanced recurrent metastatic mismatch repair proficient/microsatellite stable (pMMR/MSS) rectal cancer.", "authors": "Qadri F et al.", "journal": "Therapeutic advances in medical oncology", "date": "2026-04-12", "url": "https://pubmed.ncbi.nlm.nih.gov/41883872/", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "pubmed", "pmid": "41882705", "title": "Expression of complement pathway genes is associated with progression of idiopathic pulmonary fibrosis.", "authors": "Swaminathan AC et al.", "journal": "Respiratory research", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41882705/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41880691", "title": "CHIO3: CHemotherapy combined with immune checkpoint inhibitor for operable stage IIIA/B (N2) Non-Small cell lung cancer (AFT-46).", "authors": "Martin LW et al.", "journal": "Lung cancer (Amsterdam, Netherlands)", "date": "2026-04-12", "url": "https://pubmed.ncbi.nlm.nih.gov/41880691/", "sentiment": { "label": "negative", "score": -0.542, "confidence": 0.54 } }, { "source": "pubmed", "pmid": "41875915", "title": "Proton therapy for oropharyngeal cancer: survival, toxicity, and functional outcomes.", "authors": "Vargas CE", "journal": "Lancet (London, England)", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41875915/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41874669", "title": "Risk factors for immune checkpoint inhibitor colitis: a retrospective multi-center cohort study using electronic health records.", "authors": "Chu DHT et al.", "journal": "Cancer immunology, immunotherapy : CII", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41874669/", "sentiment": { "label": "negative", "score": -0.052, "confidence": 0.05 } }, { "source": "pubmed", "pmid": "41874648", "title": "Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV).", "authors": "Mollica V et al.", "journal": "Cancer immunology, immunotherapy : CII", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41874648/", "sentiment": { "label": "positive", "score": 0.25, "confidence": 0.25 } }, { "source": "pubmed", "pmid": "41873434", "title": "Advanced artificial intelligence vs simpler models for 1-year death prediction among patients receiving hemodialysis.", "authors": "K K et al.", "journal": "JAMIA open", "date": "2026-04-12", "url": "https://pubmed.ncbi.nlm.nih.gov/41873434/", "sentiment": { "label": "positive", "score": 0.052, "confidence": 0.05 } }, { "source": "pubmed", "pmid": "41872254", "title": "Monitoring treatment response using an ultra-sensitive ctDNA assay in advanced esophagogastric cancer patients.", "authors": "Nixon AB et al.", "journal": "Scientific reports", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41872254/", "sentiment": { "label": "negative", "score": -0.527, "confidence": 0.53 } }, { "source": "pubmed", "pmid": "41864057", "title": "Impact of pathologic response and individual prognosis after neoadjuvant treatment in patients with early HER2+ and triple-negative breast cancer.", "authors": "Corti C et al.", "journal": "Breast (Edinburgh, Scotland)", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41864057/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41862950", "title": "Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study.", "authors": "Holida M et al.", "journal": "Orphanet journal of rare diseases", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41862950/", "sentiment": { "label": "positive", "score": 0.753, "confidence": 0.75 } }, { "source": "pubmed", "pmid": "41862439", "title": "Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium.", "authors": "Varga C et al.", "journal": "Blood cancer journal", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41862439/", "sentiment": { "label": "positive", "score": 0.402, "confidence": 0.4 } }, { "source": "pubmed", "pmid": "41861751", "title": "Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia.", "authors": "Rugo HS et al.", "journal": "ESMO open", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41861751/", "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "pubmed", "pmid": "41860673", "title": "Photochemical transformation of paracetamol sensitized by humic acid: pH-dependent pathways and mechanisms.", "authors": "Barrera A et al.", "journal": "Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41860673/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41860053", "title": "AGMT mCRC Registry Third-Line and Beyond: a multicentric real-world platform with integrated imaging and biosample database for later-line metastatic colorectal cancer.", "authors": "Huemer F et al.", "journal": "Future oncology (London, England)", "date": "2026-04-12", "url": "https://pubmed.ncbi.nlm.nih.gov/41860053/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41858873", "title": "Tolerance and Resistance to Targeted Therapy in NSCLC: Emerging Concepts and Strategies.", "authors": "Sanchez-Cespedes M et al.", "journal": "JTO clinical and research reports", "date": "2026-04-12", "url": "https://pubmed.ncbi.nlm.nih.gov/41858873/", "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "pubmed", "pmid": "41854411", "title": "Use of ctDNA in Older Women with ER+ Breast Cancer to Facilitate Surgical De-escalation: A Prospective, Hybrid-Decentralized Trial with Correlative Studies.", "authors": "Carleton N et al.", "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41854411/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41851467", "title": "Thymic health and immunotherapy outcomes in patients with cancer.", "authors": "Bernatz S et al.", "journal": "Nature", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41851467/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41851087", "title": "The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II study.", "authors": "Lee V et al.", "journal": "Nature communications", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41851087/", "sentiment": { "label": "negative", "score": -0.832, "confidence": 0.83 } }, { "source": "pubmed", "pmid": "41850040", "title": "Phase III trial of infigratinib versus gemcitabine/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: results and reflections on early termination of PROOF 301.", "authors": "Abou-Alfa GK et al.", "journal": "ESMO open", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41850040/", "sentiment": { "label": "positive", "score": 0.25, "confidence": 0.25 } } ] } }